Entropy Technologies LP Takes $1.03 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Entropy Technologies LP acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,585 shares of the medical equipment provider’s stock, valued at approximately $1,025,000.

Other hedge funds have also bought and sold shares of the company. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic during the third quarter worth $25,000. Innealta Capital LLC bought a new stake in shares of Hologic during the second quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic in the first quarter worth about $37,000. Sunbelt Securities Inc. bought a new position in shares of Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC grew its stake in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $79.18 on Thursday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $80.84 and a 200-day moving average price of $78.22. The company has a market cap of $18.39 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the firm earned $0.89 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Analyst Ratings Changes

HOLX has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday. Evercore ISI lifted their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada increased their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.